This site is intended for healthcare professionals
  • Home
  • /
  • Guidelines
  • /
  • Non-Hodgkin lymphoma
  • /
  • Newly diagnosed and relapsed mantle cell lymphoma:...

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Read time: 1 mins
Last updated:1st Jul 2017
Newly Diagnosed and Relapsed Mantle Cell Lymphoma: ESMO Clinical Practice Guidelines - European Society for Medical Oncology (ESMO)

Mantle cell lymphoma is a relatively uncommon subtype of lymphoid malignancy and is more often found in males than in females. These updated ESMO guidelines provide treatment recommendations for first-line and relapsed disease including the leukaemic non-nodal subtype. Also covered is a summary of recent phase II/III trials investigating dose-intensified first-line therapy in mantle cell lymphoma and a list of published clinical studies investigating molecular targeted approaches for patients in the relapsed stage.

Read full guideline